DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group C — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group C maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group c is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
DNA cross-link repair 1B (DCLRE1B) — DCLRE1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet d5mdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7A1F · 1.8 Å · ligand 2'-DEOXYADENOSINE-5'-MONOPHOSPHATE (D5M). Experimental structure, not a prediction.
What the evidence adds up to
Fanconi anaemia complementation group C is one of at least eight genetic subgroups (A–H) of a rare autosomal recessive disease characterised by spontaneous chromosomal instability and specific hypersensitivity to DNA cross-linking agents such as mitomycin C. The mean age of onset of anaemia is 8 years, and mean survival is 16 years; death usually results from complications of bone marrow failure. The gene defective in group C has been cloned, and transfection of the normal FA-C gene into mutant cells corrects the hypersensitivity to cross-linking agents and improves cell viability in vitro. An experimental trial of gene therapy for group C FA was ongoing at the National Institutes of Health as of 1998.
The FANCG protein (encoded by the gene mutated in group G) localises to the cytoplasm and nucleus and assembles in a physical complex with the FANCA protein, both in vivo and in vitro. Endogenous FANCA/FANCG complex was detected in non-FA cells and in FA cells from groups D and E. No complex was detected in specific cell lines belonging to groups A and G, while reduced levels were found in cells from groups B, C, F, and H. Wild-type levels of the complex were restored upon correction of the cellular phenotype by transfection or cell fusion, suggesting the complex is functionally significant in the FA pathway. These results connect the cellular FA phenotype to three biochemical subtypes based on levels of the FANCA/FANCG complex.
Current treatment methods rely on anaemia correction through stem cell transplantation. A 2023 literature review notes that more than 20 genes can now carry biallelic inactivating mutations causing Fanconi anaemia, and that the connection to malignancies — especially breast, skin and blood-related cancers, as well as squamous cell carcinomas — is a major concern for patients and caregivers. The same review states that modern and more efficient therapies need to be developed, but does not report any new drug or intervention that has changed clinical practice for group C or any other subgroup.
What remains missing is a completed, publicly reported gene therapy trial for group C with survival or engraftment data; any drug that has been shown to restore the FANCA/FANCG complex in group C cells in a clinical setting; and a trial design that stratifies patients by the biochemical subtype (complex levels) described in the 1999 work. No drug is mentioned in these abstracts as a treatment for Fanconi anaemia complementation group C.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Proceedings of the National Academy of Sciences · 1999 · 155 citations · open access
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA
AbstractFanconi anemia (FA) is a recessively inherited disease characterized at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to cross-linking agents. FA is genetically heterogeneous, comprising at least eight complementation groups (A-H). We report that the protein encoded by the gene mutated in complementation group G (FANCG) localizes to the cytoplasm and nucleus of the cell and assembles in a molecular complex with the FANCA protein, both in vivo and in vitro. Endogenous FANCA/FANCG complex was detected in both non-FA cells and in FA cells from groups D and E. By contrast, no complex was detected in specific cell lines belonging to groups A and G, whereas reduced levels were found in cells from groups B, C, F, and H. Wild-type levels of FANCA/FANCG complex were restored upon correction of the cellular phenotype by transfection or cell fusion experiments, suggesting that this complex is of functional significance in the FA pathway. These results indicate that the cellular FA phenotype can be connected to three biochemical subtypes based on the levels of FANCA/FANCG complex. Disruption of the complex may provide an experimental strategy for chemosensitization of neoplastic cells.
Current Opinion in Hematology · 1999 · 33 citations
The molecular and cellular biology of Fanconi anemia
AbstractFanconi anemia is a rare autosomal recessive disease characterized by multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. The mean age of onset of anemia is 8 years, and the mean survival is 16 years. Death usually results from complications of bone marrow failure. Considerable progress in Fanconi anemia research has resulted from the recent identification and cloning of three Fanconi anemia genes. The current review describes the structure and function of the Fanconi anemia genes and describes the role of the encoded Fanconi anemia proteins in a cellular pathway controlling chromosome stability.
The Keio Journal of Medicine · 1998 · 0 citations · open access
Molecular Approaches to the Treatment of Fanconi Anemia: Recent Advances.
AbstractFanconi anemia (FA) is an autosomal recessive disorder that leads to aplastic anemia. Cells from FA patients are abnormally sensitive to DNA cross-linking agents such as mitomycin C. FA consists of at least five subgroups (FA-A through-E). The genes defective in the FA-C and FA-A groups have recently been cloned. Transfection of the normal FA gene into mutant cells corrects the hypersensitivity to DNA cross-linking agents and improves cell viability in vitro. The function of the FA gene products is still unclear, however. For patients lacking a compatible bone marrow transplantation donor, an experimental trial of gene therapy for group C FA is ongoing at the National Institutes of Health.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Current and Novel Directions in Fanconi Anemia Treatment Methods - a Literature Review
AbstractFanconi anemia is a genetically-transmitted disease caused by biallelic inactivating mutations in more than 20 genes. While its main symptoms include severe anemia, other cytopenias and skin pigmentation impairments, the aspect which concerns both patients and caregivers is the connection between Fanconi anemia and the development of several malignancies, especially breast, skin and blood-related cancers, as well as squamous cell carcinomas. Current treatment methods rely on anemia correction through stem cell transplantation, however it has become more and more evident that modern and more efficient therapies need to be developed. This needs-led literature review provides an overview of the main highlights in Fanconi anemia current and emerging therapeutic directions in order to improve the patients’ quality of life.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Current and Novel Directions in Fanconi Anemia Treatment Methods - a Literature Review
AbstractFanconi anemia is a genetically-transmitted disease caused by biallelic inactivating mutations in more than 20 genes. While its main symptoms include severe anemia, other cytopenias and skin pigmentation impairments, the aspect which concerns both patients and caregivers is the connection between Fanconi anemia and the development of several malignancies, especially breast, skin and blood-related cancers, as well as squamous cell carcinomas. Current treatment methods rely on anemia correction through stem cell transplantation, however it has become more and more evident that modern and more efficient therapies need to be developed. This needs-led literature review provides an overview of the main highlights in Fanconi anemia current and emerging therapeutic directions in order to improve the patients’ quality of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
